Author:
Daneshkhah Ali,Prabhala Sravya,Viswanathan Parvathi,Subramanian Hariharan,Lin Jianan,Chang Andrew S,Bharat Ankit,Roy Hemant Kumar,Backman Vadim
Abstract
AbstractSupranucleosomal chromatin structure, including chromatin domain conformation, is involved in the regulation of gene expression and its dysregulation has been associated with carcinogenesis. Prior studies have shown that cells in the buccal mucosa carry a molecular signature of lung cancer among the cigarette-smoking population, the phenomenon known as field carcinogenesis or field of injury. Thus, we hypothesized that chromatin structural changes in buccal mucosa can be predictive of lung cancer. However, the small size of the chromatin chain (approximately 20 nm) folded into chromatin packing domains, themselves typically below 300 nm in diameter, preclude the detection of alterations in intradomain chromatin conformation using diffraction-limited optical microscopy. In this study, we developed an optical spectroscopic statistical nanosensing technique to detect chromatin packing domain changes in buccal mucosa as a lung cancer biomarker: chromatin-sensitive partial wave spectroscopic microscopy (csPWS). Artificial intelligence (AI) was applied to csPWS measurements of chromatin alterations to enhance diagnostic performance. Our AI-enhanced buccal csPWS nanocytology of 179 patients at two clinical sites distinguished Stage-I lung cancer versus cancer-free controls with an area under the ROC curve (AUC) of 0.92 ± 0.06 for Site 1 (in-state location) and 0.82 ± 0.11 for Site 2 (out-of-state location).
Funder
National Institutes of Health
National Science Foundation
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. SEER. Annual Report to the Nation 2022: Overall cancer statistics, https://seer.cancer.gov/index.html (2022).
2. Cerfolio, R. J. & Bryant, A. S. Survival of patients with true pathologic stage I non-small cell lung cancer. Ann. Thorac. Surg. 88, 917–922. https://doi.org/10.1016/j.athoracsur.2009.05.040 (2009) (discussion 922–913).
3. Fedewa, S. A. et al. State variation in low-dose computed tomography scanning for lung cancer screening in the United States. J. Natl. Cancer Inst. 113, 1044–1052. https://doi.org/10.1093/jnci/djaa170 (2021).
4. SEER. Cancer of the lung and bronchus—Cancer stat facts, SEER., 5. Bach, P. B., Silvestri, G. A., Hanger, M. & Jett, J. R. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3), 69S-77S. https://doi.org/10.1378/chest.07-1349 (2007).